[MRI-guided breast microbiospy or macrobiopsy: which is the best option for a small tumor?].

Gynecol Obstet Fertil

Pôle de gynécologie-obstétrique, hôpitaux universitaires de Strasbourg, 1, avenue Molière, 67200 Strasbourg, France.

Published: June 2014

The choice of the optimum therapeutic strategy for breast cancer depends on the histological diagnosis of the sample obtained by biopsy. The microbiopsy is the preferred method as it provides an accurate diagnosis of the histological type as well as the main prognostic factors, whilst being simple, fast and inexepensive. However, some infraclinic breast tumors are not accessible by conventional guidance due to excessive depth inside the breast, their small size or technical inability to image them by mammography or ultrasonography. In those cases, the MRI guidance may help to perform the biopsy. Most MRI biopsies are made by large-core needle that are known to alter the histological structure of the tumor and to disturb the anatomopatholgical analysis (size and surgical margin). Those are very important elements to know before treatment. Our case report details an original technique of MRI microbiopsy of a deep 4mm opacity found on the occasion of a patient's mammography. The operative specimen revealed an invasive ductal carcinoma of 4mm diameter which scored III on the Elston and Ellis scale (oestrogen and progesterone receptors tested negative and HER-2 was over-expressed). It was associated with a high grade in situ ductal carcinoma. No systemic treatment was prescribed due to the small size of the carcinoma. The development of partially or totally amagnetic microbiopsy pistols would help perform microbiopses guided by MRI.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.gyobfe.2014.04.007DOI Listing

Publication Analysis

Top Keywords

small size
8
help perform
8
ductal carcinoma
8
[mri-guided breast
4
breast microbiospy
4
microbiospy macrobiopsy
4
macrobiopsy best
4
best option
4
option small
4
small tumor?]
4

Similar Publications

Background: Cytomegalovirus (CMV) infection poses a significant risk to kidney transplant recipients. This study investigated CMV disease incidence, outcomes, and management challenges in racial and ethnic minority populations following kidney transplantation.

Methods: This single-center, mixed-methods study included a retrospective cohort analysis of kidney transplant recipients (n = 58) and qualitative surveys of healthcare providers.

View Article and Find Full Text PDF

Rectifying the Crosstalk between the Skeletal and Immune Systems Improves Osteoporosis Treatment by Core-Shell Nanocapsules.

ACS Nano

January 2025

Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, China.

Contemporary osteoporosis treatment often neglects the intricate interactions among immune cells, signaling proteins, and cytokines within the osteoporotic microenvironment. Here, we developed core-shell nanocapsules composed of a cationized lactoferrin core and an alendronate polymer shell. By tuning the size of these nanocapsules and leveraging the alendronate shell, we enabled precise delivery of small interfering RNA targeting the Semaphorin 4D gene (siSema4D) to specific bone sites.

View Article and Find Full Text PDF

Introduction: Patients with moderate-to-severe atopic dermatitis (AD), a body surface area (BSA) of ≤ 40%, and an itch numerical rating scale (NRS) score of ≥ 7 ("BARI itch dominant") have been characterized as an important group to consider for the oral janus kinase (JAK) 1/2 inhibitor baricitinib (BARI). Herein we aim to evaluate quality of life (QoL) and functioning outcomes in adult patients with BSA ≤ 40% and itch NRS ≥ 7 at baseline (BL) who received BARI 4 mg in the topical corticosteroid (TCS) combination trial BREEZE-AD7.

Materials: BREEZE-AD7 was a randomized, double-blind, placebo-controlled, parallel-group outpatient study involving adult patients with moderate-to-severe AD who received once-daily placebo or 2-mg or 4-mg BARI in combination with TCS for 16 weeks.

View Article and Find Full Text PDF

Objective: We aimed to investigate the effect of adding "rapid decelerations" and "vibrations" during a SemontPLUS maneuver on the dynamics of the inner ear and the success rate of canalolithiasis repositioning.

Methods: We used a previously described upscaled (5×) in vitro model of the posterior semicircular canal of the inner ear to analyze the trajectory of a single and clumped surrogate otolith particle (metallic sphere) during a SemontPLUS maneuver (-60 degrees below earth horizontal) on a repositioning chair (TRV). We compared the angular displacement of these particles with and without the application of "vibrations" or "rapid decelerations" using TRV.

View Article and Find Full Text PDF

The role of Anti-Müllerian hormone in women health.

Ginekol Pol

January 2025

Department of Clinical Dietetics, Faculty of Health Sciences, Medical University of Warsaw, Poland, Poland.

Anti-Müllerian hormone (AMH), also known as Müller duct inhibitory factor and primarily known for its role in sexual differentiation. In female fetuses, AMH production by granulosa cells begins around the 36th week of gestation and continues in women until menopause. It is becoming more significant in the endocrine and gynecological diagnosis of adult women.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!